MarketBeat
06 Aug 2026, 05:04 UTC · 13w ago
RxSight Q2 Earnings Call Highlights
Impact · against what's priced in
RXST faces significant headwinds as core product sales declined 19% and the company withdrew its full-year guidance, signaling operational instability. While the Alcon collaboration provides a critical capital cushion and validation, it does not offset the immediate deterioration in organic growth and margin compression.
- RXST−0.60
No priced-in read yet
- In context
Core product sales fell 19% year-over-year to $27.2 million and LAL unit volume dropped 9%, while the withdrawal of full-year 2026 guidance suggests internal uncertainty under new leadership.
Read from the article alone
